Nanomedicines in gastroenterology and hepatology

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 4, 2015, Pages 195-204

  Lamprecht, Alf ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ATOVAQUONE; CLODRONIC ACID; DOXORUBICIN; HEPARIN; INSULIN; LIPOSOME; LOW MOLECULAR WEIGHT HEPARIN; MILTEFOSINE; NANOCARRIER; NANOMATERIAL; NANOWIRE; PENTAMIDINE; PRIMAQUINE; QUANTUM DOT; SMALL INTERFERING RNA; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; DRUG;

DRUG DELIVERY SYSTEM; DRUG RELEASE; GASTROENTEROLOGY; GASTROINTESTINAL DISEASE; HEPATITIS; HEPATOLOGY; HISTOPLASMOSIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INTERNAL MEDICINE; LEISHMANIASIS; LISTERIOSIS; LIVER FIBROSIS; NANOMEDICINE; NANOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SALMONELLOSIS; STOMACH ULCER; ULCERATIVE COLITIS; ANIMAL; GASTROINTESTINAL DISEASES; LIVER DISEASES; PROCEDURES;

ANIMALS; GASTROENTEROLOGY; GASTROINTESTINAL DISEASES; HUMANS; LIVER DISEASES; NANOMEDICINE; NANOSTRUCTURES; PHARMACEUTICAL PREPARATIONS;

EID: 84926422163     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.37     Document Type: Review

References (108)

1. Gabizon A. A., Lyass O., Berry G. J. & Wildgust M. Cardiac safety of pegylated liposomal doxorubicin (Doxil/Caelyx) demonstrated by endomyocardial biopsy in patients with advanced malignancies. Cancer Invest. 22, 663-669 (2004
2. Duncan R. Polymer conjugates as anticancer nanomedicines. Nat. Rev. Cancer 6, 688-701 (2006
3. Reddy L. H. & Couvreur P. Nanotechnology for therapy and imaging of liver diseases. J. Hepatol. 55, 1461-1466 (2011
4. Medina-Sánchez M., Miserere S. & Merkoçi A. Nanomaterials and lab on a-chip technologies. Lab Chip 12, 1932-1943 (2012
5. Zheng G., Patolsky F., Cui Y., Wang W. U. & Lieber C. M. Multiplexed electrical detection of cancer markers with nanowire sensor arrays. Nat. Biotechnol. 23, 1294-1301 (2005
6. Jin Z. & Hildebrandt N. Semiconductor quantum dots for in vitro diagnostics and cellular imaging. Trends Biotechnol. 30, 394-403 (2012
7. Laroui H., Rakhya P., Xiao B., Viennois E. & Merlin D. Nanotechnology in diagnostics and therapeutics for gastrointestinal disorders. Dig. Liver Dis. 45, 995-1002 (2013
8. Csaba N., Garcia-Fuentes M. & Alonso M. J. The performance of nanocarriers for transmucosal drug delivery. Expert Opin. Drug Deliv. 3, 463-478 (2006
9. Schlüter A. & Lamprecht A. Current developments for the oral delivery of heparin. Curr. Pharm. Biotechnol. 15, 640-649 (2014
10. Bakhru S. H., Furtado S., Morello A. P. & Mathiowitz E. Oral delivery of proteins by biodegradable nanoparticles. Adv. Drug Deliv. Rev. 65, 811-821 (2013
11. Paulo C. S., Pires das Neves R. & Ferreira L. S. Nanoparticles for intracellular-targeted drug delivery. Nanotechnology 22, 494002 (2011
12. Lamprecht A. & Benoit J. P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P glycoprotein inhibition. J. Control. Release 112, 208-213 (2006
13. Yameen B., et al. Insight into nanoparticle cellular uptake and intracellular targeting. J. Control. Release 190, 485-499 (2014
14. Biswas S. & Torchilin V. P. Nanopreparations for organelle-specific delivery in cancer. Adv. Drug Deliv. Rev. 66, 26-41 (2014
15. Bazile D., et al. Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. J. Pharm. Sci. 84, 493-498 (1995
16. Moghimi S. M. & Hunter A. C. Capture of stealth nanoparticles by the body's defences. Crit. Rev. Ther. Drug Carrier Syst. 18, 527-550 (2001
17. Dams E. T., et al. Technetium 99m labeled liposomes to image experimental colitis in rabbits: comparison with technetium 99m-HMPAO-granulocytes and technetium 99m-HYNIC-IgG. J. Nucl. Med. 39, 2172-2178 (1998
18. Abra R. M., et al. The next generation of liposome delivery systems: recent experience with tumor-targeted sterically-stabilized immunoliposomes and active-loading gradients. J. Liposome Res. 12, 1-3 (2002
19. Metselaar J. M., Mastrobattista E. & Storm G. Liposomes for intravenous drug targeting: design and applications. Mini Rev. Med. Chem. 2, 319-329 (2002
20. Simone E., Ding B. S. & Muzykantov V. Targeted delivery of therapeutics to endothelium. Cell Tissue Res. 335, 283-300 (2009
21. Tabata Y., Inoue Y. & Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14, 1677-1685 (1996
22. Lamprecht A., Schäfer U. & Lehr C. M. Size dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18, 788-793 (2001
23. Hassani S., Pellequer Y. & Lamprecht A. Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm. Res. 26, 1149-1154 (2009
24. Lamprecht A. IBD: selective nanoparticle adhesion can enhance colitis therapy. Nat. Rev. Gastroenterol. Hepatol. 7, 311-312 (2010
25. Mahmoud A. A. & Warren K. S. Algorithms in the diagnosis and management of exotic diseases. XXIV. Leishmaniases. J. Infect. Dis. 136, 160-163 (1977
26. Alving C. R., et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc. Natl. Acad. Sci. USA 75, 2959-2963 (1978
27. Alving C. R., et al. Liposomes in leishmaniasis: therapeutic effects of antimonial drugs 8 aminoquinolines and tetracycline. Life Sci. 26, 2231-2238 (1980
28. Alving C. R. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol. Today 2, 101-107 (1986
29. Cauchetier E., et al. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int. J. Parasitol. 30, 777-783 (2000
30. Escobar P., Yardley V. & Croft S. L. Activities of hexadecylphosphocholine (miltefosine), AmBisome and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45, 1872-1875 (2001
31. Morrissey D. V., et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat. Biotechnol. 23, 1002-1007 (2005
32. Carmona S., et al. Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles. Mol. Pharm. 6, 706-717 (2009
33. Kurata N., et al. Specific protein delivery to target cells by antibody-displaying bionanocapsules. J. Biochem. 144, 701-707 (2008
34. Oishi J., et al. A gene-delivery system specific for hepatoma cells and an intracellular kinase signal based on human liver-specific bionanocapsules and signal-responsive artificial polymer. Int. J. Pharm. 396, 174-178 (2010
35. Jung J., et al. Bio-nanocapsule conjugated with liposomes for in vivo pinpoint delivery of various materials. J. Control. Release 126, 255-264 (2008
36. Feng M., et al. Recombinant high-density lipoprotein complex as a targeting system of nosiheptide to liver cells. J. Drug Target. 16, 502-508 (2008
37. Feng M., Cai Q., Huang H. & Zhou P. Liver targeting and anti-HBV activity of reconstituted HDL-acyclovir palmitate complex. Eur. J. Pharm. Biopharm. 68, 688-693 (2008
38. Llovet J. M. & Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res. 20, 2072-2079 (2014
39. Moghimi S. M., Hunter A. C. & Murray J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283-318 (2001
40. Barraud L., et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J. Hepatol. 42, 736-743 (2005
41. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT01655693?term=NCT01655693&rank=1 (2014
42. Zhou Q., Sun X., Zeng L., Liu J. & Zhang Z. A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine 5, 419-423 (2009
43. Lacoeuille F., et al. In vivo evaluation of lipid nanocapsules as a promising colloidal carrier for paclitaxel. Int. J. Pharm. 344, 143-149 (2007
44. Lacoeuille F., Garcion E., Benoit J. P. & Lamprecht A. Lipid nanocapsules for intracellular drug delivery of anticancer drugs. J. Nanosci. Nanotechnol. 7, 4612-4617 (2007
45. Needham D., Anyarambhatla G., Kong G. & Dewhirst M. W. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 60, 1197-1201 (2000
46. Lorusso D., et al. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome). Ann. Oncol. 18, 1159-1164 (2007
47. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT00617981?term=NCT00617981&rank=1 (2014
48. Lv L. H., et al. Anticancer drugs cause release of exosomes with heat shock proteins from human hepatocellular carcinoma cells that elicit effective natural killer cell antitumor responses in vitro. J. Biol. Chem. 287, 15874-15885 (2012
49. Yamamoto H., et al. Hepatocellular carcinoma in cirrhotic livers: detection with unenhanced and iron oxide-enhanced MR imaging. Radiology 195, 106-112 (1995
50. Ward J., et al. Hepatocellular carcinoma in the cirrhotic liver: double-contrast MR imaging for diagnosis. Radiology 216, 154-162 (2000
51. Bhartia B., Ward J., Guthrie A. & Robinson P. J. Hepatocellular carcinoma in cirrhotic livers: double contrast thin-section MR imaging with pathologic correlation of explanted tissue. AJR Am. J. Roentegenol. 180, 577-584 (2003
52. Tanimoto A. & Kuribayashi S. Application of superparamagnetic iron oxide to imaging of hepatocellular carcinoma. Eur. J. Radiol. 58, 200-216 (2006
53. Kelkar S. S. & Reineke T. M. Theranostics: combining imaging and therapy. Bioconjug. Chem. 22, 1879-1903 (2011
54. Hu J., et al. Theranostic Au cubic nano-aggregates as potential photoacoustic contrast and photothermal therapeutic agents. Theranostics 4, 534-545 (2014
55. Liu Y., et al. Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer. Nanoscale 6, 3231-3242 (2014
56. Knittel T., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 117, 1205-1221 (1999
57. Beljaars L., et al. Characteristics of the hepatic stellate cell-selective carrier mannose 6 phosphate modified albumin (M6P(28)-HSA). Liver 21, 320-328 (2001
58. Adrian J. E., Poelstra K. & Kamps J. A. Addressing liver fibrosis with liposomes targeted to hepatic stellate cells. J. Liposome Res. 17, 205-218 (2007
59. Adrian J. E., et al. Effects of a new bioactive lipid-based drug carrier on cultured hepatic stellate cells and liver fibrosis in bile duct-ligated rats. J. Pharmacol. Exp. Ther. 321, 536-543 (2007
60. Beljaars L., et al. Successful targeting to rat hepatic stellate cells using albumin modified with cyclic peptides that recognize the collagen type VI receptor. J. Biol. Chem. 275, 12743-12751 (2000
61. Du S. L., et al. Cyclic Arg Gly Asp peptide-labeled liposomes for targeting drug therapy of hepatic fibrosis in rats. J. Pharmacol. Exp. Ther. 322, 560-568 (2007
62. Mandal A. K., Das S., Basu M. K., Chakrabarti R. N. & Das N. Hepatoprotective activity of liposomal flavonoid against arsenite-induced liver fibrosis. J. Pharmacol. Exp. Ther. 320, 994-1001 (2007
63. Sato Y., et al. Resolution of liver cirrhosis using vitamin A coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat. Biotechnol. 26, 431-442 (2008
64. Li T., et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev. 22, 845-854 (2013
65. Jain A. K. & Jain S. K. Development and characterization of nanolipobeads-based dual drug delivery system for H. pylori targeting. J. Drug Target. 21, 593-603 (2013
66. Jain A. K., Agarwal A., Agrawal H. & Agrawal G. P. Double liposome based dual-drug delivery system as vectors for effective management of peptic ulcer. Liposome Res. 22, 205-214 (2012
67. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21, 797-802 (2010
68. Oyen W. J. G., et al. Scintigraphic evaluation of experimental colitis in rabbits. J. Nucl. Med. 38, 1596-1600 (1997
69. Dams E. T., et al. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J. Nucl. Med. 41, 622-630 (2000
70. Awasthi V. D., Goins B., Klipper R. & Phillips W. T. Accumulation of PEG-liposomes in the inflamed colon of rats: potential for therapeutic and diagnostic targeting of inflammatory bowel diseases. J. Drug Target. 10, 419-427 (2002
71. Bartneck M., et al. Liposomal encapsulation of dexamethasone modulates cytotoxicity inflammatory cytokine response and migratory properties of primary human macrophages. Nanomedicine 10, 1209-1220 (2014
72. Arranz A., et al. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J. Control. Release 165, 163-172 (2013
73. Sakhalkar H. S., et al. Leucocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl Acad. Sci. USA 100, 15895-15900 (2003
74. Sakhalkar H. S., et al. Enhanced adhesion of ligand-conjugated biodegradable particles to colitic venules. FASEB J. 19, 792-794 (2005
75. Yu L., et al. Exosomes with membrane-associated TGF β1 from gene-modified dendritic cells inhibit murine EAE independently of MHC restriction. Eur. J. Immunol. 43, 2461-2472 (2013
76. Yang X., Meng S., Jiang H., Chen T. & Wu W. Exosomes derived from interleukin 10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis. Scand. J. Gastroenterol. 45, 1168-1177 (2010
77. Bruewer M., et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J. Immunol. 171, 6164-6172 (2003
78. Nakase H., et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 292, 15-21 (2000
79. Lamprecht A., et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299, 775-781 (2001
80. Lamprecht A., Yamamoto H., Takeuchi H. & Kawashima Y. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315, 196-202 (2005
81. Pellequer Y., Meissner Y., Ubrich N. & Lamprecht A. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J. Pharmacol. Exp. Ther. 321, 726-733 (2007
82. Pastorelli L., et al. Oral colonic-release low molecular weight heparin: an initial open study of Parnaparin-MMX for the treatment of mild to moderate left-sided ulcerative colitis. Aliment. Pharmacol. Ther. 28, 581-588 (2008
83. Schmidt C., et al. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa: a first in vivo study in human patients. J. Control. Release 165, 139-145 (2013
84. Jubeh T. T., Barenholz Y. & Rubinstein A. Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes. Pharm. Res. 21, 447-453 (2004
85. Jubeh T. T., Nadler-Milbauer M., Barenholz Y. & Rubinstein A. Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase TMN and SOD. J. Drug Target. 14, 155-163 (2006
86. Jubeh T. T., Antler S., Haupt S., Barenholz Y. & Rubinstein A. Local prevention of oxidative stress in the intestinal epithelium of the rat by adhesive liposomes of superoxide dismutase and tempamine. Mol. Pharm. 2, 2-11 (2005
87. Wachsmann P., Moulari B., Béduneau A., Pellequer Y. & Lamprecht A. Surfactant-dependence of nanoparticle treatment in murine experimental colitis. J. Control. Release 172, 62-68 (2013
88. Lamprecht A., Yamamoto H., Takeuchi H. & Kawashima Y. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control. Release 104, 337-346 (2005
89. Laroui H., et al. Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138, 843-853 (2010
90. Pertuit D., et al. 5 amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control. Release 123, 211-218 (2007
91. Moulari B., Pertuit D., Pellequer Y. & Lamprecht A. The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 29, 4554-4560 (2008
92. Vong L. B., Tomita T., Yoshitomi T., Matsui H. & Nagasaki Y. An orally administered redox nanoparticle that accumulates in the colonic mucosa and reduces colitis in mice. Gastroenterology 143, 1027-1036 (2012
93. Kriegel C. & Amiji M. Oral TNF α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 150, 77-86 (2011
94. Tahara K., et al. Oral nuclear factor-?B decoy oligonucleotides delivery system with chitosan modified poly(D, L lactide co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials 32, 870-878 (2011
95. Wilson D. S., et al. Orally delivered thioketal nanoparticles loaded with TNF α-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9, 923-928 (2010
96. Niebel W., Walkenbach K., Béduneau A., Pellequer Y. & Lamprecht A. Nanoparticle-based clodronate delivery mitigates murine experimental colitis. J. Control. Release 160, 659-665 (2012
97. Xiao B., et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 146, 1289-1300 (2014
98. Laroui H., et al. Fab'-bearing siRNA TNFα-loaded nanoparticles targeted to colonic macrophages offer an effective therapy for experimental colitis. J. Control. Release 186, 41-53 (2014
99. Moulari B., Beduneau A., Pellequer Y. & Lamprecht A. Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J. Control. Release 188, 9-17 (2014
100. Bodger K., et al. Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 55, 973-977 (2006
101. Rhodes J. M., Black R. R. & Savage A. Altered lectin binding by colonic epithelial glycoconjugates in ulcerative colitis and Crohn's disease. Dig. Dis. Sci. 33, 1359-1363 (1988
102. Prados J., et al. Colon cancer therapy: recent developments in nanomedicine to improve the efficacy of conventional chemotherapeutic drugs. Anticancer Agents Med. Chem. 13, 1204-1216 (2013
103. Lahaye M. J., et al. USPIO-enhanced MR imaging for nodal staging in patients with primary rectal cancer: predictive criteria. Radiology 246, 804-811 (2008
104. Pickhardt P. J. Recent developments in colorectal imaging. Curr. Opin. Gastroenterol. 31, 76-80 (2015
105. Suzuki R., et al. Effective anti-tumor activity of oxaliplatin encapsulated in transferrin-PEG liposome. Int. J. Pharm. 346, 143-150 (2008
106. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT00689065?term=NCT00689065&rank=1 (2013
107. US National Library of Medicine. Clinical.Trials.gov [online], https://Clinical.Trials.gov/ct2/show/NCT00361842?term=NCT00361842&rank=1 (2012
108. Kirui D. K., Khalidov I., Wang Y. & Batt C. A. Targeted near-IR hybrid magnetic nanoparticles for in vivo cancer therapy and imaging. Nanomedicine 9, 702-711 (2013